Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.

Next Previous
Trial Profile

A Phase II, Randomized, Assessor-blind, Multicenter, Multi-dose, Placebo-controlled Study Assessing the Safety and Anti-coronavirus Response of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate SARS-CoV-2 Infection.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brequinar (Primary) ; Dipyridamole (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions
  • Acronyms CCBCRISIS04
  • Sponsors Clear Creek Bio

Most Recent Events

  • 16 Jun 2022 Status changed from recruiting to discontinued.
  • 01 Feb 2022 Status changed from not yet recruiting to recruiting.
  • 04 Jan 2022 Planned initiation date changed from 1 Dec 2021 to 1 Jan 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top